Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
InnoCare Pharma Ltd. ( (HK:9969) ) has issued an update.
InnoCare Pharma Limited has announced estimated financial results for 2024, highlighting an expected revenue of approximately RMB1,010 million, marking a 37% increase from the previous year, driven by the success of Orelabrutinib. The company has also reduced its net loss by about 30%, attributed to the inclusion of Orelabrutinib in medical insurance and its approval as a treatment option in China, strengthening InnoCare’s market position.
More about InnoCare Pharma Ltd.
InnoCare Pharma Limited is a biopharmaceutical company primarily focused on developing therapies for cancer and autoimmune diseases. Their key product, Orelabrutinib, is a BTK inhibitor used for the treatment of marginal zone lymphoma (MZL), among other indications, and has gained approval and recommendations in China.
YTD Price Performance: -14.22%
Average Trading Volume: 4,664,018
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: HK$8.02B
For a thorough assessment of 9969 stock, go to TipRanks’ Stock Analysis page.